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Evaluation of unmet clinical needs in
prophylaxis and treatment of venous
thromboembolism in at-risk patient groups:
pregnancy, elderly and obese patients
Benjamin Brenner1,2*, Roopen Arya3, Jan Beyer-Westendorf4,5, James Douketis6,7, Russell Hull8, Ismail Elalamy2,9,
Davide Imberti10 and Zhenguo Zhai11
Abstract
Background: Venous thromboembolism (VTE) accounts for an estimated 900,000 cases per year in the US alone
and constitutes a considerable burden on healthcare systems across the globe.
Objective: To understand why the burden is so high, qualitative and quantitative research was carried out to gain
insights from experts, guidelines and published studies on the unmet clinical needs and therapeutic strategies in
VTE prevention and treatment in three populations identified as being at increased risk of VTE and in whom VTE
prevention and treatment were regarded as suboptimal: pregnant women, the elderly and obese patients.
Methodology: A gap analysis methodology was created to highlight unmet needs in VTE management and to
discover the patient populations considered most at risk. A questionnaire was devised to guide qualitative
interviews with 44 thrombosis and haemostasis experts, and a review of the literature on VTE in the specific patient
groups from 2015 to 2017 was completed. This was followed by a Think Tank meeting where the results from the
research were discussed.
Results: This review highlights the insights gained and examines in detail the unmet needs with regard to VTE risk-
assessment tools, biomarkers, patient stratification methods, and anticoagulant and dosing regimens in pregnant
women, the elderly and obese patients.
Conclusions: Specifically, in pregnant women at high risk of VTE, low-molecular-weight heparin (LMWH) is the
therapy of choice, but it remains unclear how to use anticoagulants when VTE risk is intermediate. In elderly
patients, evaluation of the benefit of VTE prophylaxis against the bleeding risk is particularly important, and a head-
to-head comparison of efficacy and safety of LMWH versus direct oral anticoagulants is needed. Finally, in obese
patients, lack of guidance on anticoagulant dose adjustment to body weight has emerged as a major obstacle in
effective prophylaxis and treatment of VTE.
Keywords: Venous thromboembolism, Elderly, Pregnant, Pregnancy, Obese, Obesity, Anticoagulants, Low-
molecular-weight heparin
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Background
Venous thromboembolism (VTE), comprising deep vein
thrombosis (DVT) and pulmonary embolism (PE),
remains a major concern for healthcare systems globally.
Despite improved prophylaxis and treatment options,
and current risk-assessment tools, morbidity and
mortality related to VTE remains high in patient pop-
ulations such as pregnant women, the elderly and
obese patients [1].
VTE is the main cause of mortality in women during
the post-partum period [2]. Acute VTE is linked to sub-
stantial long-term mortality in the elderly (21% of 991
patients in a Swiss cohort study with a median follow-up
time of 30 months) [3]. Patients with VTE who are mor-
bidly obese are more likely to have extended hospital
and intensive care unit stays [4]. Thus, the suboptimal
use of anticoagulants in these patients and the increased
cost burden related to longer hospital stays needs to be
addressed.
A lack of adequate population-specific risk-assessment
tools, along with uncertainties around correct dosing
regimens and concern over increased bleeding risk, may
be linked to these elevated mortality and morbidity rates
[5, 6]. In addition, although guidelines exist on prophy-
laxis and treatment of these patients, discrepancies occur
between recommendations, leading to low adherence by
physicians to such guidance [7–9]. Moreover, there is a
paucity of evidence on these patient populations due to
problems of recruiting individuals to randomised con-
trolled trials (RCT), which may be linked to patients’ co-
morbidities, frailty and concern over foetal development
and maternal well-being [10, 11].
Considering the above, it is important to examine the
evidence presented in guidelines, published studies and
reviews, and through expert opinion, in order to high-
light unmet needs and inconsistencies in clinical prac-
tice, with a view to homogenising VTE prevention and
treatment strategies.
Methodology
Quantitative mapping was performed to identify key
opinion leaders who were active online and in publica-
tions, patient advocacy groups, scientific associations,
editorial boards, guidelines, clinical trials and congress
activities in the thrombosis and haemostasis field. From
this list, experts were selected from a range of countries
dependent on their availability to attend a telephone
interview. Forty-four key opinion leaders were contacted
between February and August 2017 from 12 different
countries or regions: Canada, Brazil, five European coun-
tries, Middle East, Africa, Russia, China and Japan. The
interviews followed a pre-determined questionnaire [see
Additional file 1] and a gap analysis was carried out on
the information received. The data revealed areas of
unmet need with regard to VTE management with can-
cer, the critically ill, pregnant women, the elderly and
obese patients. Of these five patient groups, the first two
were discussed in a previous paper and the latter three
were chosen for discussion in this paper [12] additional
file 2. A comprehensive literature search was conducted
in PubMed, Cochrane Library and current guidelines
(January 2015 to December 2018) using the terms: preg-
nant, pregnancy, obese, obesity, elderly and venous
thromboembolism. Further insights were gained during
a Thrombosis Think Tank meeting in Paris in February
2018, during which the authors discussed the findings
from the qualitative and quantitative research in order
to establish unmet clinical needs and examine thera-
peutic approaches to bridging the gaps in VTE manage-
ment in these three patient groups.
Prophylaxis and treatment of VTE during pregnancy and
post-partum
Despite a relatively low absolute risk of VTE of 1.2 per
1000 pregnancies, VTE remains a leading cause of ma-
ternal mortality in developed countries [2, 13, 14]. VTE
can occur at any time during pregnancy, but increases
20-fold during the post-partum period [13]. Timely diag-
nosis depends on awareness of the condition and recog-
nition of risk factors, including a family history of or
previous thrombophilia (heritable: antithrombin defi-
ciency, protein C deficiency, protein S deficiency, factor
V Leiden, prothrombin gene mutation; acquired: anti-
phospholipid antibodies, persistent lupus anticoagulant
and/or persistent moderate/high titre anticardiolipin
antibodies and/or β2-glycoprotein 1 antibodies) or VTE,
obesity, increased maternal age, reduced mobility and
hospitalisation, and is critical to avoid VTE-induced
mortality [13].
Guideline recommendations for pregnant and post-natal
women at risk of VTE
Various guidelines on prevention and treatment of VTE
in ante- and post-partum women and women with re-
current pregnancy loss exist, and of the experts inter-
viewed, the American College of Chest Physicians
(ACCP) and the Royal College of Obstetricians and
Gynaecologists (RCOG) were indicated as the main
guidelines being followed (Table 1).
However, due to a lack of evidence-based data in this
population, the recommendations provided by national
and international guidelines often vary and have not re-
cently been updated, apart from the American Society of
Hematology (ASH) guidelines on VTE in pregnancy
published in 2018 [10, 14]. For example, the guidelines
on prophylaxis of VTE in women after a caesarean sec-
tion show divergent recommendations. A study by Pal-
merola, et al., comparing guideline recommendations for
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thromboprophylaxis after a caesarean section from
RCOG, the American College of Obstetricians and Gy-
necologists, and ACCP found that 85, 1 and 35% of pa-
tients, respectively, would receive pharmacologic
prophylaxis if the guidance were followed, thus
highlighting significant gaps in consistency between rec-
ommendations [15].
The underlying cause is the lack of RCTs in this pa-
tient population and over-reliance on observational data,
especially case–control studies that provide a lower level
of evidence [16]. Many studies on prevention and man-
agement of VTE in pregnancy are performed on a small
patient population due to patient enrolment difficulties,
as women are reluctant to take additional medication,
particularly when it is administered through injections.
For example, the TIPPS study aimed to examine the ef-
fects of dalteparin in pregnancy and recruited only 292
pregnant women with thrombophilia over 12 years [17].
Thrombophilia was defined in this study as two abnor-
mal tests and no normal tests for protein S, protein C or
antithrombin; two positive tests for anticardiolipin im-
munoglobulin M (IgM) (> 30 U/ml), anticardiolipin im-
munoglobulin G (IgG) (> 30 U/ml), anti-β2 glycoprotein
IgG (> 20 U/ml), anti-β2 glycoprotein IgM (> 20 U/ml),
or lupus anticoagulant; and one positive test for factor V
Leiden (heterozygous or homozygous) or prothrombin
gene defect (heterozygous or homozygous) [17]. Most of
the studies involving pregnant women provide outcomes
without achieving statistical significance and, due to an
absence of high-level evidence, prophylaxis is often not
provided [16]. Insights from the qualitative research car-
ried out for this paper noted that in China, country-level
guidelines have not yet been developed and there is an
inconsistent approach to prophylaxis.
VTE risk-assessment models and biomarkers
A history of VTE or heritable thrombophilia (factor V Lei-
den mutation, prothrombin gene mutation, antithrombin
deficiency, protein C deficiency, protein S deficiency) are
established risk factors of VTE in pregnant women [18];
however, the data from the qualitative interviews under-
lined the need to develop new tools to identify additional
risk factors for pregnant women. The STRATHEGE score
study by Chauleur, et al., involving pregnant women with
at least one VTE risk factor, established a simple scoring
system to evaluate VTE risk, but the low event rate meant
the discriminatory power of the score could not be
assessed [19]. However, a subsequent study, aimed at
evaluating the effectiveness of the STRATHEGE score fol-
lowing its implementation in 21 French maternity units,
demonstrated a significantly reduced risk of VTE and pla-
cental vascular complications of 50 and 30%, respectively
[20]. Another VTE risk score, which was developed
through a logistic regression model and based on 14 risk
factors, including comorbidities and VTE history in the
first 6 weeks post-partum, offers a benefit of predicting
VTE events in the early post-partum period more accur-
ately than current models provided by UK and Swedish
national guidelines, but further validation is needed [21].
Alternatively, the EThIG trial assessed a risk evaluation
strategy and effectiveness of heparin prophylaxis in low-
risk and high/very high-risk pregnant women groups.
Risk-stratified dalteparin prophylaxis was associated with
a low incidence of symptomatic VTE and few adverse
events [22].
In terms of biomarkers, it is known that D-dimer
levels, an exclusion criterion for VTE, increase during
pregnancy and peak in the third trimester at levels above
the conventional cut-off, making them of little use [23].
Several studies have looked at recording D-dimer refer-
ence intervals during the three trimesters in healthy
pregnancy and suggested pregnancy-associated cut-off
levels that may assist clinical decision-making on VTE
prophylaxis [23, 24]. Soluble fibrin monomer forms a
complex with fibrinogen in the bloodstream early in co-
agulation, and measuring levels of the complex has also
Table 1 Guidelines followed by experts interviewed
Question Expert opinion
What guidelines and clinical protocols do you use for prevention and treatment of VTE, including guidance
on dose and duration, in ante- or post-partum pregnant women and in women with recurrent pregnancy
loss?
• ACCP/CHEST
• ISTH
• Italian Society of Thrombosis and
Haemostasis
• RCOG
• National guidelines
• Involved in the generation of
national guidelines
• Follow own experience
• No guidelines are being followed
ACCP/CHEST, American College of Chest Physicians; ISTH, International Society of Thrombosis and Haemostasis; RCOG, Royal College of Obstetricians and
Gynaecologists; VTE, venous thromboembolism
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been proposed as a marker to screen for VTE [25]. How-
ever, recent studies have questioned the predictive utility
of all conventional and candidate VTE biomarkers for
use during pregnancy and the puerperium [26, 27].
In summary, further research is needed to develop
more precise risk-assessment tools and improve the
diagnostic value of biomarkers in order to tailor throm-
boprophylaxis for this patient population.
Prophylaxis and treatment of VTE in ante- and post-partum
periods
Thromboprophylaxis is recommended in all pregnant
women with an estimated VTE risk above 5% but is ad-
vised against for a risk below 1%. However, the approach
to the management of pregnant women with an esti-
mated risk between 1 and 5% remains debatable
(Table 2) [2, 14, 30].
The 2015 RCOG guidelines state that prophylaxis
should be used from the start of pregnancy in women
with four VTE risk factors, from week 28 in those with
three risk factors, and women with two risk factors
should receive 10 days of post-partum prophylaxis [13].
This implies that nearly half of pregnant women are eli-
gible for post-partum prophylaxis [31]. The ACCP
guidelines suggest that the presence of one of the major
risk factors or two minor risk factors, or one following
emergency caesarean section indicates a post-partum
VTE risk > 3% [28].
In the post-partum period, the risk of VTE is high in
the first 2 weeks after giving birth. Guidelines [13, 28]
suggest that prophylaxis should continue for 6 weeks
post-partum, although experts noted that, considering
the increase in risk is greatest in the first 2–3 weeks
only, this recommendation may be contested, unless a
history of VTE is present in a patient. Since VTE risk is
high in the first week following a caesarean section,
thromboprophylaxis is given post-partum for 10 days in
the UK following all non-elective caesarean sections and
for elective caesarean-section patients with one other
VTE risk according to RCOG guidance [13]. This may
account for the observed decrease in maternal deaths
from 1985 to 2014 [32]. In Germany, post-partum
prophylaxis depends on the type of caesarean section,
i.e., prophylaxis after elective caesarean section lasts for
10–14 days and after an emergency caesarean section is
extended for up to 3 months.
Direct oral anticoagulants (DOAC) should not be used
in pregnancy, or when breastfeeding, as their effects on
the foetus or the new-born child are currently unknown
[14, 33, 34]. However, despite guideline recommendations,
Table 2 Subpopulations of pregnant women recommended for LMWH prophylaxis or treatment
Question Expert opinion Guideline recommendations
Which subpopulation(s) of pregnant women, ante-
or post-partum, or those with recurrent pregnancy
loss, should be treated with LMWHs such as
enoxaparin?
• Women with recurrent pregnancy loss
• No evidence to support use of LMWH
to prevent recurrent pregnancy loss
• Women with antiphospholipid
syndrome or with heterozygosity of
factor V Leiden mutation
• Those undergoing IVF
• Those with previous unprovoked or
provoked VTE
• LMWH is recommended in the case of
a severe event such as placenta
abruption, intrauterine foetus death or
VTE
• ACCP/CHEST [28]: For women requiring long-term
VKA treatment who are attempting pregnancy, a
switch to LMWH is recommended. In women with
no VTE risk factors, prophylaxis is not recom-
mended following a caesarean section. No routine
prophylaxis for patients following assisted
reproduction
• ASH [14]: Prophylaxis is only advised for women
undergoing assisted reproductive therapy with
severe ovarian hyperstimulation syndrome. For
women with previous unprovoked or provoked
VTE, ante-partum prophylaxis is advised. For
women with antithrombin deficiency who are
homozygous for the factor V Leiden regardless of
family history, ante-partum and post-partum
prophylaxis is recommended. In those with protein
S or C deficiency, post-partum prophylaxis is
advised
• Italian Society of Thrombosis and Haemostasis [29]:
Ante- and post-partum prophylaxis is recom-
mended for women with thrombophilic defects.
LMWH is recommended in women with prior VTE.
Ante- and post-partum LMWH prophylaxis is sug-
gested for women with prior obstetric complica-
tions and one thrombophilic defect
• RCOG [13]: LMWH is the preferred anticoagulant to
treat acute VTE and for antenatal and post-natal
prophylaxis. 10 days prophylaxis with LMWH is rec-
ommended after an emergency caesarean section
and after a planned caesarean section if there are
additional risk factors
ACCP/CHEST, American College of Chest Physicians; ASH, American Society of Hematology; IVF, in-vitro fertilisation; LMWH, low-molecular-weight heparin; RCOG,
Royal College of Obstetricians and Gynaecologists; VKA, vitamin K antagonists; VTE, venous thromboembolism
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clinical experience in Germany (as documented subject-
ively by local opinion leaders) and a recent review of 137
pregnant women with DOAC exposure suggest that ad-
ministration of DOACs during early pregnancy does not
indicate a high risk of embryopathy, and pregnancy ter-
mination for these women may not be necessary [35].
In summary, low-molecular-weight heparin (LMWH)
is the preferred anticoagulant for both prophylaxis and
treatment during pregnancy. However, guidelines and
opinions differ on how to stratify risk, the most effective
duration of prophylaxis and the safety of DOACs during
pregnancy.
LMWH dose adjustment
In pregnant women at very high risk of thromboembolic
complications and especially in those with acute VTE,
monitoring of anti-Xa activity is often recommended
(and performed), aiming to ensure adequate dosing of
LMWH, which can be challenging in pregnant women.
However, there is considerable uncertainty about the
strategy (peak or trough anti-Xa levels) and the target
ranges, the impact of these target ranges on clinical out-
comes, and the accuracy and reproducibility of the as-
says [36]. Taken together, the experts agreed that anti-
Xa monitoring in pregnant women at very high risk for
thromboembolism is widely used and likely beneficial,
but also agreed that many details of this strategy are still
under debate, indicating a large unmet need for better
evidence in this setting (Table 3).
Clinical practice in the UK recommends dose adjust-
ment as per body weight in pregnant women for both
treatment and prophylaxis, and, as a result, only a few
breakthrough clots occur, although generous dosage given
as recommended by RCOG guidelines may be a reason
for these outcomes [13]. In Israel, anti-Xa levels are
measured for both treatment and prophylaxis, although
usually approximately 60% of women on a therapeutic
dose and 20% of women on a prophylactic dose need
these doses to be adjusted at around 20–25 weeks. In Italy,
the experts interviewed used a fixed dose of LMWH for
prophylaxis in pregnant women with a history of
thrombosis.
Some of the experts have questioned the ideal dose of
LMWH for thromboprophylaxis and treatment in
pregnancy. The ongoing Highlow study, an RCT of
intermediate-dose LMWH adjusted to actual body weight
versus fixed low-dose nadroparin, may inform this clinical
question for thromboprophylaxis [37].
Challenges in the management of VTE in elderly patients
With life expectancy increasing in the developed world,
a new definition of ‘the elderly’ should be considered,
which should include significant comorbidities such as
coronary, hepatic, renal and cognitive functions, as well
as frailty, rather than focusing on age alone (Table 4).
The interviewed experts noted that impaired renal and
cognitive functions, but not age per se, may be the major
factors influencing the decision for or against antithrom-
botic therapy, as well as treatment outcome. However,
26 of the interviewees acknowledged that such patients
are usually excluded from clinical trials, which limits
evidence and guideline recommendations [40]. Evidence
shows that the risk of venous thrombosis, which associ-
ates with illnesses characteristic to advanced age,
increases exponentially with age, but thromboprophy-
laxis remains suboptimal in this patient group due to
fear of bleeding since thrombotic and bleeding risk
profiles usually overlap in this population [41, 42].
VTE risk-assessment models and biomarkers in the elderly
The experts agreed that VTE risk assessment in elderly pa-
tients should include comorbidities, concomitant medica-
tions and frailty to identify those at high risk of VTE.
Furthermore, biomarkers may help to increase the predict-
ive performance of VTE risk-assessment strategies. In the
setting of primary VTE prophylaxis in acutely ill medical
Table 3 Methods of identifying optimal anticoagulant dose in thrombophilic pregnant women and those with pregnancy loss
Question Expert opinion Guideline recommendations
What method do you use to identify optimal dose
of anticoagulants in thrombophilic pregnant women
and those with pregnancy loss, e.g., PK/PD
modelling or other methods?
• Anti-Xa monitoring
• Factor Xa activity in prophylaxis is not
measured
• Routine monitoring of the dose is not
recommended, the clinical picture of
each patients is more important
• PK/PD data is not usually used
• The PK/PD profile is required
• LMWH dose adjusted to weight
• Fixed dose
• Full-dose enoxaparin for high-risk
patients
• ACCP/CHEST [28]: Anti-Xa measuring is not advised.
Intermediate-dose LMWH dose is recommended in
pregnant women with a history of VTE, with throm-
bophilia or with a risk of pregnancy loss
• ASH [14]: Routine anti-Xa monitoring to guide dos-
ing is not advised
• Italian Society of Thrombosis and Haemostasis [29]:
Monitoring platelet count during prophylaxis with
LMWH is advised. No evidence to suggest use of
anti-Xa monitoring to adjust LMWH dose
• RCOG [13]: Titration of LMWH dose against the
woman’s booking or early pregnancy weight is
advised. Routine measurement of anti-Xa is not rec-
ommended except in women < 50 kg or > 90 kg
ACCP/CHEST, American College of Chest Physicians; ASH, American Society of Hematology; LMWH, low-molecular-weight heparin; PK/PD, pharmacokinetic/
pharmacodynamic; RCOG, Royal College of Obstetricians and Gynaecologists; VTE, venous thromboembolism
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patients, the MAGELLAN study found that in patients with
an average age of 71.4 years, high concentrations of D-
dimer (> 2 μgmL− 1 mean) at day 10 were a predictor of in-
creased VTE risk for up to 35 days [43]. Subsequently, this
informed the selection criteria for the APEX study, which
used a D-dimer level of ≥2x the upper limit of normal to
examine primary VTE prevention for acutely ill medical pa-
tients aged 60–74 [44]. The ADJUST-PE study demon-
strated that an age-adjusted D-dimer cut-off of age × 10 in
patients > 50 years was successful in ruling out patients at
risk of VTE [45]. However, using this biomarker to drive
primary VTE prophylaxis decisions may not be effective in
elderly patients due to an increase of circulating D-dimer in
this patient population, which may not necessarily be linked
to increased VTE risk [42, 46]. Consequently, further stud-
ies need to establish a more accurate threshold for bio-
markers such as D-dimer before they can be routinely used
for risk stratification and treatment decisions.
At the same time, elderly fragile patients are at an in-
creased risk of falls and bleeding, but bleeding scores are
unreliable in this population and their use is limited [47].
Moreover, elderly women seem to be at 20–25% higher
risk of bleeding than men [11, 48, 49].
The experts noted that VTE risk-assessment guidance
differs across countries. Further work is needed to de-
velop a simple-to-use risk-assessment score for elderly
patients that incorporates age, gender, comorbidities and
bleeding risk.
Consideration of anticoagulants for prophylaxis in the
elderly
There is little evidence regarding ideal anticoagulants for
prophylaxis of the elderly largely due to the under-
representation of this group of patients in clinical stud-
ies, owing to several comorbidities which increase the
chance of exclusion from a trial [40]. Therefore, certain
guideline recommendations may have been extrapolated
from studies with younger cohorts and may not necessarily
extend to this patient population [42]. Patients > 75 years of
age have an increased risk of VTE [42] and, according to
the ACCP, hospitalised medical patients > 70 years should
be offered pharmacological VTE prophylaxis with fonda-
parinux, LMWH or unfractionated heparin (UFH) [29].
Yet, a systematic review and meta-analysis comparing effi-
cacy and safety of LMWH versus UFH reported an overall
increase in the rate of major haemorrhage with heparin
prophylaxis compared to no prophylaxis [50]. However, the
LMWH group showed a statistically significant bleeding
risk reduction over the UFH group and LMWH demon-
strated a better efficacy profile than UFH in terms of redu-
cing DVT risk (Table 5) [50].
The experts agreed that thromboprophylaxis should
only be prescribed following careful benefit–risk assess-
ments, but it is essential to consider drug compliance,
major and non-major bleeding risks, and comorbidities,
including renal function, hypertension, infections and
coronary artery disease. Evidence from expert interviews
demonstrates disparities in thromboprophylaxis practice
from country to country. In general, elderly patients are
underprophylaxed due to the perceived increased risk of
bleeding in this population [51]. In Germany, evidence
from a VTE registry shows that patients > 65 years of
age are often underprophylaxed out of hospital and in-
creasing public awareness on VTE risk situations has
been suggested as a possible solution [52]. In France, ac-
cording to national experts, elderly patients often receive
Table 4 Practical considerations for treating elderly patients with high risk of VTE
Question Expert opinion Guideline recommendations
Are there any practical considerations when treating elderly
patients with high risk of VTE, such as specific risk factors, contra-
indications, comorbidities or practicalities of administration?
• Higher bleeding risk
• Traditional regimens
increase the risk of
bleeding
• The risk of internal
bleeding
• Need to evaluate the
risk of stroke through
bleeding
• Renal function may
be compromised
• Dosage due to the
reduction in kidney
function
• Dosage taking into
consideration contra-
indications
• Co-medications
• Lack of clinical trials
• Affordability is an
issue
All recommendations are non-age specific.
ACCP/CHEST [28]:
• Hepatic failure, severe renal failure, rheumatic disease,
current cancer and age≥ 80 are all independent risk
factors for bleeding
NICE [38]:
• Balance the patient’s risk of VTE against their bleeding
risk
SIGN [39]:
• Patients undergoing total hip replacement with
increased risk of bleeding should be given mechanical
prophylaxis alone
ACCP/CHEST, American College of Chest Physicians; NICE, The National Institute for Health and Care Excellence; SIGN, Scottish Intercollegiate Guidelines Network;
VTE, venous thromboembolism
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prophylaxis but many of these patients are prophylaxed
with either the incorrect type of anticoagulant or a sub-
optimal dose, therefore increasing the bleeding risk with-
out achieving antithrombotic effect [53]. In China, in-
hospital prophylaxis is insufficient and a lack of VTE
knowledge and understanding of the guidelines is lead-
ing to non-standard approaches to thromboprophylaxis
[54]. Published data from Italian national registries have
shown that in contrast to widely used extended prophy-
laxis following a surgical procedure, medical prophylaxis
is rare [55].
Expert opinion suggests that extended prophylaxis of
35 days should be given for patients at high risk of VTE,
such as post-surgery or cancer patients (Table 6).
Table 5 Subgroups of elderly patients for whom LMWH may be the optimal choice
Question Expert opinion Guideline recommendations
In which subgroups of elderly patients would
you consider LMWHs, such as enoxaparin, the
optimal choice?
• Only if the patient has a specific
condition
• In patients with cancer and VTE
• In patients with ACS
• Used in percutaneous coronary
interventions, ACS and thrombolytic
therapy
• Those with a history of internal
bleeding
• LMWH preferred due to the ability to
change dosage based on kidney
function and age
• Intermediate risk PE
• Patients with acute PE who do not
use DOACs
• Patients with comorbidities, GI
problems and chronic inflammatory
disease
• Patients with provoked VTE post-
operatively
• LMWH used with inpatients but not
used with outpatients
All recommendations are non-age specific.
ACCP/CHEST [28]:
• Acutely ill hospitalised patients at increased risk of
thrombosis
• Critically ill patients
• Outpatients with solid tumours who have additional risk
factors for VTE and low bleeding risk
NICE [38]:
• Patients with renal impairment needing pharmacological
VTE prophylaxis
• People with myeloma or pancreatic cancer receiving
chemotherapy
• People receiving palliative care
• Those admitted to the critical care unit
• 1 month of VTE prophylaxis for patients with fragility
fractures of the pelvis, hip or proximal femur
• 10 days of LMWH for people undergoing elective hip
replacement surgery
• 7 days minimum VTE prophylaxis with LMWH for patient
undergoing open vascular surgery or major endovascular
procedures, lower limb amputation
SIGN [39]:
• Patients undergoing total hip replacement should receive
prophylaxis with LMWH
• Patients with cancer and cancer surgery
• In patients with non-haemorrhagic stroke at high risk of
VTE
• Patients with suspected PE or DVT should receive
therapeutic doses
ACCP/CHEST, American College of Chest Physicians; ACS, acute coronary syndrome; DOAC, direct oral anticoagulant; DVT, deep vein thrombosis; GI,
gastrointestinal; LMWH, low-molecular-weight heparin; NICE, The National Institute for Health and Care Excellence; PE, pulmonary embolism; SIGN, Scottish
Intercollegiate Guidelines Network; VTE, venous thromboembolism
Table 6 Extended prophylaxis in elderly patients
Question Expert opinion Guideline recommendations
Should extended prophylaxis be
used in elderly patients, e.g., for hip
fractures?
• In patients with cancer
• In patients undergoing surgery
• Hip/knee replacements
• In patients with multiple fractures at
risk of recurrent VTE
• Injections can only be used for 2
weeks, oral is the preferred treatment
• Generally given for 10–14 days but can
be extended to 30–35 days
• Primary prophylaxis is currently
recommended for 35 days
• Recommended for 1 month but often
extended for 3 months
• This should only be for very high-risk
patients but we don’t know how to
identify them
• Yes, but length of time is not well
defined
All recommendations are non-age specific.
ACCP/CHEST [28]:
• Extended-duration thromboprophylaxis up to 35 days reduces VTE
in hip replacement, hip fracture and abdominal malignancy surgery
NICE [38]:
• There is a recommendation for research by the NICE guideline
committee regarding extended-duration prophylaxis for patients
undergoing elective total hip replacement surgery
SIGN [39]:
• Following total hip replacement, particularly those with previous
VTE
ACCP/CHEST, American College of Chest Physicians; NICE, The National Institute for Health and Care Excellence; SIGN, Scottish Intercollegiate Guidelines Network;
VTE, venous thromboembolism.
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This statement was supported by Dentali, et al., 2016,
who conducted a pooled analysis that suggested a poten-
tial benefit of extended antithrombotic prophylaxis in
acutely ill patients [56]. Indeed, the EXCLAIM trial
showed reduced rates of VTE in medically ill patients >
75 years of age when LMWH was administered for up to
38 days following hospital discharge; however, this was
counterbalanced by an increase in major bleeding [57].
Therefore, extended prophylaxis should be assessed on
an individual basis [58].
VTE treatment and secondary prevention after VTE in
elderly patients
Elderly patients receiving therapeutic anticoagulation for
VTE are at increased risk of long-term mortality with
comorbid burden, polypharmacy and a low level of physical
activity as predictors of major bleeding, one of the most
common causes of death [3]. Thus, selection of the optimal
antithrombotic agent, its dose and duration of treatment,
and whether this should continue beyond hospitalisation is
particularly important. Although LMWH remains an
option for hospitalised, elderly patients with different
comorbidities such as chronic inflammatory conditions,
gastrointestinal system problems, poor renal function, ac-
tive cancer, acute or chronic lung or heart conditions, and
acute infections, extended-duration treatment with LMWH
is rare, mainly due to its inconvenience and cost [59, 60].
As a consequence, short courses of initial LMWH therapy
are followed by oral anticoagulation with a vitamin K antag-
onists (VKA) such as warfarin. During the last decade,
DOACs have taken the place of LMWH/VKAs in acute
and long-term VTE treatment due to the convenience of
administration and an excellent dose-response relationship
without the need for monitoring or frequent dose adjust-
ments [61]. Indeed, several reviews examining study evi-
dence on DOACs compared to VKAs for VTE treatment in
patients ≥75 years of age have demonstrated better efficacy
and safety of DOACs over VKAs, with no increase in the
risk of bleeding [62, 63]. However, when the different
DOACs are examined individually, varying profiles are re-
vealed. The AMPLIFY trial noted improved efficacy and
safety of apixaban (10mg twice daily for 7 days followed by
5mg twice daily for 6months) compared to standard ther-
apy (enoxaparin followed by warfarin) in patients ≥75 years
[64], whereas the RE-COVER II trial, which compared dabi-
gatran to warfarin, found that efficacy and risk of bleeding
increased exponentially with age with dabigatran and de-
creased with warfarin [65]. The Hokusai-VTE study, com-
paring edoxaban to warfarin, observed an increased
bleeding risk linked to age regardless of treatment, but
noted a reduction in recurrent VTE for patients > 80 years
of age on the DOAC regimen [66]. In the EINSTEIN-DVT
and PE trials, there was a 1.4% reduction in recurrent VTE
events and a 3.3% reduction in major bleeding in patients
≥75 years of age receiving rivaroxaban compared to stand-
ard enoxaparin/VKA treatment [67].
The elderly subpopulations of patients ≥75 years of age
in these trials, however, consist of small sample sizes
from 13 to 43% of the total study populations [63]. In
addition, the majority of these trials compared DOACs
to VKAs, and clinical trials are now needed to directly
compare extended treatment with LMWHs to treatment
with DOACs in elderly patients ≥75 years of age, along
with a need for real-life evidence in elderly patients with
a high risk of DOAC accumulation [62].
In summary, more studies need to be carried out to
establish the most effective and safe antithrombotic
treatment for elderly patients outside the hospital set-
ting. Although DOACs are considered convenient in
these situations, studies on their safety have produced
varying results.
Thromboprophylaxis and treatment of VTE in obese
patients
Obesity is increasing rapidly around the world, and it pre-
sents a significant health burden [68]. Adult obesity is clas-
sified into three categories: class I obesity is defined by a
body mass index (BMI) of 30.0–34.9 kg/m2; class II obesity
by a BMI of 35.0–39.9 kg/m2; and class III obesity, or severe
obesity, by a BMI ≥40.0 kg/m2 [69]. Weight is a VTE risk
factor when a BMI exceeds 30 kg/m2 [68], and BMI has a
strong linear relationship with the incidence of VTE [4].
The inflammatory and metabolic perturbations associated
with obesity are thought to provoke a hypercoagulability
state in these patients, and central obesity plus high fibrino-
gen levels may be considered as clinical markers [70]. Gen-
etically pre-determined elevated BMI is associated with a
57% higher risk of VTE (odds ratio 1.57; 95% confidence
interval 1.08–1.97; p = 0.003), as shown by Mendelian ran-
domisation analysis between BMI- and VTE-associated
genetic variants [71]. Presence of other risk factors of VTE,
including hospitalisation, pregnancy and use of combined
oestrogen–progestin hormonal contraceptives, increases
VTE risk in obese patients and exacerbates the severity of
VTE [72–74]. An association between elevated BMI and
VTE risk has also been recently identified in paediatric pa-
tients [75]. Despite greater understanding, a number of
questions remain unanswered concerning a definition of
high-risk subpopulations who are obese and who may
benefit from thromboprophylaxis, the choice of anticoagu-
lants and selection of optimal regimens for thrombopro-
phylaxis, and treatment of VTE in obese patients.
Guideline recommendations for obese patients
Clinical practice guidelines such as, National Institute
for Health and Care Excellence (NICE), ASH and Inter-
national Society of Thrombosis and Haemostasis high-
light the need for further research regarding dosing
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regimens for obese patients [14, 76, 77]. Indeed, the ex-
perts interviewed considered that prophylaxis and treat-
ment for obese patients should be stratified into
subgroups but this is not fully reflected in current guide-
lines (Table 7).
In certain specific patient subpopulations, such as
pregnant women with a BMI ≥40, guidelines suggest
prophylactic LMWH dosage appropriate to a patient’s
weight should be considered [13], whereas bariatric
surgery patients should be given a higher dose of
LMWH in combination with graduated elastic compres-
sion stockings or intermittent pneumatic compression
devices [79]. It is also suggested to avoid dose capping of
LMWH, especially in patients with cancer, and to
administer LMWH as a twice-daily regimen to allow an
adequate total dose to be administered [78, 80].
Due to limited published data on the safety of DOACs,
guidelines do not recommend DOACs in patients with a
BMI > 40 kg/m2 or > 120 kg, and pharmacokinetic/phar-
macodynamic data suggest that drug exposure, the peak
concentration and half-life of DOACs can be compro-
mised by obesity, leading to underexposure in severely
obese patients [76].
Anticoagulants, doses and regimens in prophylaxis
The evidence for using anticoagulant thromboprophy-
laxis in obese patients is scarce according to the experts,
as obese (BMI > 30 kg/m2) and severely obese (BMI > 40
kg/m2) patients are under-represented in clinical studies.
Despite this, the physicians interviewed prefer LMWHs
over DOACs for thromboprophylaxis of obese patients.
A recent pooled data analysis from 11 out of 14 primary
studies highlighted the advantages of weight-based or
higher-than-fixed dosing of enoxaparin, which increased
the probability of achieving desired anti-Xa levels [81].
However, due to insufficient evidence and quality of
studies on LMWH dose adjustment, caution should be
taken in patients with a weight > 120–125 kg [81]. In-
deed, in the UK, NICE have highlighted the need for fur-
ther research regarding dose strategies for obese patients
before recommendations can be made [56]. In Israel, the
experts indicated that weight-adjusted regimens are
mostly used for thromboprophylaxis in obese patients,
and the Canadian experts noted that empiric LMWH
dose regimens based on a patient’s weight have been in-
troduced in some hospitals in Canada: patients < 40 kg
are given a reduced dose of LMWH (e.g., enoxaparin 30
mg daily) whereas patients > 100 kg receive a higher dose
of LMWH, typically increased by 50% (e.g., enoxaparin
60mg daily or dalteparin 7500 international units [IU]
daily). With the latter option, however, they suggest a
dose limit should be introduced to avoid overtreatment.
The type of LMWH is important, as clearance of differ-
ent LMWH varies in obese patients. Qualitative inter-
views revealed divergence of country-specific clinical
practices and clinicians’ opinions regarding adjustment
Table 7 High-risk obese patient subgroups that may require variations of VTE treatment
Question Expert opinion Guideline recommendations
Do considerations for treatment of obese
patients at high risk of VTE vary between
patient subgroups?
• Subgroups in obese patients are poorly
studied
• Treatments vary between different patient
weight groups: obese, morbidly obese
• The subgroup of obese patients > 120 kg
is problematic
• Different weight groups require different
anticoagulant treatments
• Standardised treatment regimens with
enoxaparin exist in some hospitals
• Medical and surgical obese patients need
to be considered as two separate groups
• Bariatric surgery or non-bariatric surgery
patients and medical patients should be
considered separately
• Surgical obese patients should be
differentiated into those undergoing
bariatric surgery or any other surgery
• There are differences in how these
patients are defined as high risk
ACCP [28]:
• Graduated compression stockings are recommended for
severely obese patients considering long distance travel
ISTH [76]:
• Standard dosing of DOACs is recommended for obese
patients with a weight < 120 kg
• DOACs should not be used in obese patients with a
weight > 120 kg but if they are then drug-specific peak
and trough levels should be checked
NICE [38]:
• Further research is needed regarding dose strategies of
LMWH for very obese people (BMI > 35) who are admitted
to hospital or receiving day procedures
• Mechanical prophylaxis is recommended for patients
undergoing bariatric surgery
RCOG [13]:
• Risk of VTE during pregnancy increases with a BMI > 25
and ante-partum immobilisation
SOGC [30]:
• Recommended dose increases for UFH, enoxaparin,
dalteparin and tinzaparin are indicated for obese pregnant
women
Thrombosis Canada [78]:
• Obese patients between 40–100 kg are recommended
higher doses of dalteparin, enoxaparin and tinzaparin than
patients < 40 kg to be taken once daily. This dose is
increased to twice daily for those weighing 101–120 kg
ACCP, American College of Chest Physicians; BMI, body mass index; DOAC, direct oral anticoagulant; ISTH, International Society of Thrombosis and Haemostasis;
LMWH, low-molecular-weight heparin; NICE, National Institute for Health and Care Excellence; RCOG, Royal College of Obstetricians and Gynaecologists; SOGC,
Society of Obstetricians and Gynaecologists of Canada; UFH, unfractionated heparin; VTE, venous thromboembolism
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of prophylactic LMWH doses to a patient’s weight or
BMI (Fig. 1).
Several recent studies have demonstrated advantages
of adjusting prophylactic dosage to a patient’s weight to
achieve adequate VTE control. High-dose UFH, 7500 IU
three-times daily, or enoxaparin, 40 mg twice daily, were
more effective in reducing the risk for VTE from 1.48 to
0.77% in patients > 100 kg and discharged from hospital
than low-dose UFH (5000 IU twice/three-times daily) or
enoxaparin (40 mg once daily), with no increase in
bleeding being reported [82]. Similarly, the comparative
ITOHENOX study, which evaluated two enoxaparin reg-
imens (60 mg versus 40 mg) in acutely ill obese patients
with a BMI ≥30 kg/m2, found normal anti-Xa levels in
69 and 31% of patients receiving 60 mg and 40mg daily,
respectively, with no significant difference in bleeding
rates between the two groups [83]. Patients with an aver-
age BMI of 62.1 kg/m2 achieved adequate goal peak anti-
Xa levels more frequently when weight-based higher-
dose enoxaparin (0.5 mg/kg) was administered compared
with a weight-adjusted lower-dose (0.4 mg/kg) or fixed-
dose (40 mg daily) regimen [84].
Weight-based enoxaparin dosage for prophylaxis ap-
pears more effective than BMI-stratified dosing in
achieving anti-Xa levels that are presumed adequate for
VTE prophylaxis in severely obese women (BMI ≥40 kg/
m2) after caesarean delivery [80]. Similarly, another
study has shown that post-caesarean weight-based
thromboprophylaxis with enoxaparin at 0.5 mg/kg twice
daily in women with a BMI ≥35 kg/m2 is more effective
than fixed dosage of 40 mg daily in achieving prophylac-
tic anti-Xa levels [85].
Efficacy and safety of DOACs in thromboprophylaxis of
obese patients has not been adequately investigated. Vari-
ous Phase III studies of DOACs have a subpopulation of
obese patients, but many of those studies are inconsistent
in their design, and stratification based on BMI or weight
is not always available [79]. Fixed-dose DOACs are gener-
ally thought to be inappropriate for patients with a high
BMI, specifically a BMI in the range of 30–40 kg/m2 and
in severely obese with a BMI > 40 kg/m2 [80].
In summary, due to conflicting data from a small
amount of research-based studies in this population, it is
uncertain whether dose adjustment should be based on
weight, BMI or a fixed-dose regimen (Fig. 2).
Treatment of VTE in obese patients
The majority of experts from the qualitative interviews
agree on adjusting LMWH dose to a patient’s weight for
treatment of VTE (Fig. 1).
In obese patients with a weight > 100 kg and acute VTE,
twice-daily dosing with LMWH is suggested. In selected
patients, measurement of peak anti-factor Xa levels may
be appropriate to ensure that an adequate anticoagulant
effect is attained. Therapeutic levels of anticoagulant effect
are not established with LMWH therapy and do not ap-
pear to correlate with treatment efficacy (VTE recurrence
risk) or safety (bleeding risk) [86]. Nonetheless, target peak
therapeutic levels have been suggested to be 0.6–1.0 IU/
mL for obese patients receiving a twice-daily treatment
dose of LMWH and > 1.0 IU/mL for patients receiving
once-daily LMWH [86–88].
Recent studies on DOACs showed similar efficacy and
safety to that of VKAs in patients with high, normal and
low body weight and acute VTE, with similar rates of
bleeding episodes recorded [89]. A study by Ihaddadene,
et al., and the experts’ personal clinical experience sug-
gest that DOACs, such as rivaroxaban, at a fixed dose is
effective in patients with a weight range of 50–150 kg
[90]. Moreover, analysis of prospectively collected non-
Fig. 1 Should weight-based or fixed dosing be used for prophylaxis and treatment of VTE?
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interventional data in stroke prevention in patients with
a BMI range of 13.7–57.2 kg/m2 and atrial fibrillation or
VTE revealed that obese patients treated with a standard
dose of DOACs had the lowest rate of cardiovascular
events, major bleeding events and all-cause mortality
than the normal-weight patients, suggesting that fixed-
dose DOACs may provide a safe option in obese patients
[91]. Creatinine clearance is greater in obese patients;
therefore, it may be suggested to use DOACs with less
dependence on renal clearance, such as apixaban or riv-
aroxaban, in these patients [92]. However, the experts
interviewed agreed that further evidence needs to be
generated to recommend DOACs for obese patients in a
routine clinical setting.
Anticoagulants and dose regimens in bariatric surgery
The number of patients undergoing bariatric surgery
procedures is increasing, and VTE prevention research
in this area warrants more attention to define best prac-
tices. Patients undergoing bariatric surgery are consid-
ered at high VTE risk due, in part, to such patients
having multiple non-surgical factors that increase risk,
and VTE is also likely one of the most common causes
of death in this population [93, 94]. In the US, bariatric
surgery is the most common surgery [95]. However,
studies carried out on patients undergoing bariatric sur-
gery do not necessarily reflect up-to-date practices accord-
ing to the experts, as patients are currently discharged
from hospital 1–2 days post-surgery and therefore throm-
boprophylaxis should be considered in an out-of-hospital
setting. Evidence-based guidance is sparse, but it suggests
that the LMWH dose should be increased for prophylaxis,
with a weight-based or staggered dose, after bariatric sur-
gery [39]. Indeed, a systematic review, which sought to
discover if weight-adjusted thromboprophylaxis is safe
and effective in the post-operative period, showed that
prophylactic doses of heparin, adjusted to a patient’s
weight, achieved a significantly better reduction in the in-
hospital VTE rate when compared with non-adjusted
prophylactic dose (0.54% versus 2.0%) [94]. A risk-
assessment tool was designed to predict the risk of post-
discharge VTE, which was 0.29% in a 30-day post-
bariatric surgery period with a 28-fold increase in mortal-
ity in those with VTE (p < 0.001) [94]. More than 80% of
VTE events occur in a post-hospitalisation period, and this
proportion is likely to become larger as bariatric surgery is
increasingly done as a day procedure or with a minimal
hospital stay [94]. In a prophylactic setting following bar-
iatric surgery, anti-Xa measurements (trough levels if in-
tent is to identify over-dosing and peak levels if intent is
to identify under-dosing) should be considered 3–5 days
after starting prophylaxis, but patients typically are sent
home 1–2 days post-operatively and are in the acute-
phase setting, so routinely measuring anti-Xa levels may
be impractical. The experts considered that the determin-
ation of VTE is typically made pre-procedure, so anti-Xa
levels appear uninformative in stratifying patients for
prophylaxis.
Conclusions
The findings from the interviews with experts, the Throm-
bosis Think Tank meeting and the desktop research high-
light the inconsistency of guideline recommendations and
the heterogeneous views of physicians on effective primary
and secondary VTE prophylaxis and VTE prevention in
these high-risk medical patients. There is a paucity of
user-friendly, population-adapted VTE risk-assessment
models to provide reliable stratification of medical patients
Fig. 2 Should dose adjustment be based on weight or related to percentage of body fat?
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for anticoagulant therapy, and current biomarkers show
promise when investigated in research studies, but many
have little value in the routine clinical setting [43].
LMWH remains the anticoagulant of choice in preg-
nant women and obese patients, where DOACs are not
currently recommended. Similarly, in the elderly,
LMWH demonstrates a better safety and efficacy profile
than UFH for thromboprophylaxis. LMWH dose adjust-
ment remains a significant problem in obese patients
and pregnant women, with conflicting views on adjust-
ment of prophylactic dose related to weight or BMI.
Simple guidance needs to be generated for clinicians, as
many are not familiar with the use of pharmacokinetic
data to adjust dosing regimens.
Although further clinical studies are needed to address
the VTE prophylaxis gaps, ultimately, global communi-
cation on best-practice strategies and homogeneity of
guideline recommendations through increasing research
data would help join up the gaps in clinical practice and
improve the outcomes of medical patients.
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